Symbols / VAXX
VAXX Chart
About
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 25.36K |
| Enterprise Value | -15.44M | Income | -56.93M | Sales | — |
| Book/sh | 0.11 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 57 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | 0.00 | P/C | — |
| EV/EBITDA | 0.28 | EV/Sales | — | Quick Ratio | 1.76 |
| Current Ratio | 1.89 | Debt/Eq | 113.12 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.38 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-08 07:00 | ROA | -48.34% |
| ROE | -150.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 112.91M |
| Shs Float | 112.87M | Short Float | 108.73% | Short Ratio | 13.97 |
| Short Interest | — | 52W High | 0.05 | 52W Low | 0.00 |
| Beta | 1.44 | Avg Volume | 10.34K | Volume | 257.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-5.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-08 | init | Baird | — → Outperform | $7 |
| 2022-04-27 | init | Evercore ISI Group | — → In-Line | — |
| 2021-12-07 | init | Jefferies | — → Buy | $18 |
| 2021-12-06 | init | B of A Securities | — → Buy | $21 |
- VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka ue, 20 Jan 2026 08
- Net Worth Update: Senator Rick Scott Made an Estimated $3.1M in the Stock Market Last Month - Quiver Quantitative Sun, 12 Oct 2025 07
- VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka Wed, 11 Feb 2026 20
- CDC signs off on change in newborn hepatitis b vaccine schedule - Seeking Alpha ue, 16 Dec 2025 08
- Net Worth Update: Senator Rick Scott Made an Estimated $863.6K in the Stock Market Last Month - Quiver Quantitative Sun, 10 Aug 2025 07
- Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech Wed, 15 May 2024 07
- Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace Mon, 22 Apr 2024 07
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance Fri, 19 Apr 2024 07
- Why measles is resurging—and the rise of vaccine hesitancy, with Adam Ratner - The University of Chicago hu, 20 Feb 2025 08
- VAXX Stock Price and Chart — OTC:VAXX - TradingView Wed, 10 Nov 2021 08
- Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Leader - Forbes hu, 14 Nov 2024 08
- Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat Sat, 27 Nov 2021 00
- Why Are Some Parents Still Hesitant to Vaccinate Their Child Against RSV? - The American Journal of Managed Care® (AJMC®) Wed, 26 Jun 2024 07
- Opinion | Vax Quack Lacks Facts - The New York Times Sat, 30 Aug 2025 07
- Vaxxinity Issues Shareholder Letter - GlobeNewswire Fri, 19 Apr 2024 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -53.96M | -73.04M | -123.96M |
| TotalUnusualItems | -43.00K | 12.00K | -11.27M |
| TotalUnusualItemsExcludingGoodwill | -43.00K | 12.00K | -11.27M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.93M | -75.22M | -137.18M |
| ReconciledDepreciation | 2.23M | 1.68M | 1.10M |
| ReconciledCostOfRevenue | 0.00 | 1.94M | |
| EBITDA | -54.00M | -73.02M | -135.23M |
| EBIT | -56.24M | -74.71M | -136.34M |
| NetInterestIncome | 1.39M | 745.00K | -831.00K |
| InterestExpense | 696.00K | 514.00K | 840.00K |
| InterestIncome | 2.09M | 1.26M | 9.00K |
| NormalizedIncome | -56.89M | -75.23M | -125.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.93M | -75.22M | -137.18M |
| TotalExpenses | 58.28M | 75.98M | 125.14M |
| TotalOperatingIncomeAsReported | -58.28M | -75.98M | -125.08M |
| DilutedAverageShares | 125.94M | 76.59M | |
| BasicAverageShares | 125.94M | 76.59M | |
| DilutedEPS | -0.60 | -1.79 | |
| BasicEPS | -0.60 | -1.79 | |
| DilutedNIAvailtoComStockholders | -56.93M | -75.22M | -137.18M |
| NetIncomeCommonStockholders | -56.93M | -75.22M | -137.18M |
| NetIncome | -56.93M | -75.22M | -137.18M |
| NetIncomeIncludingNoncontrollingInterests | -56.93M | -75.22M | -137.18M |
| NetIncomeContinuousOperations | -56.93M | -75.22M | -137.18M |
| TaxProvision | 0.00 | 0.00 | |
| PretaxIncome | -56.93M | -75.22M | -137.18M |
| OtherIncomeExpense | -43.00K | 12.00K | -11.27M |
| OtherNonOperatingIncomeExpenses | -8.37M | ||
| GainOnSaleOfSecurity | -43.00K | 12.00K | -11.27M |
| NetNonOperatingInterestIncomeExpense | 1.39M | 745.00K | -831.00K |
| InterestExpenseNonOperating | 696.00K | 514.00K | 840.00K |
| InterestIncomeNonOperating | 2.09M | 1.26M | 9.00K |
| OperatingIncome | -58.28M | -75.98M | -125.08M |
| OperatingExpense | 58.28M | 75.98M | 123.20M |
| ResearchAndDevelopment | 35.90M | 47.63M | 71.38M |
| SellingGeneralAndAdministration | 22.39M | 28.35M | 51.83M |
| GeneralAndAdministrativeExpense | 22.39M | 28.35M | 51.83M |
| OtherGandA | 22.39M | 28.35M | 51.83M |
| GrossProfit | 0.00 | -1.87M | |
| CostOfRevenue | 0.00 | 1.94M | |
| TotalRevenue | 0.00 | 0.00 | 66.00K |
| OperatingRevenue | 0.00 | 0.00 | 66.00K |
| Line Item | 2023-12-31 | ||
|---|---|---|---|
| TreasurySharesNumber | 0.00 | ||
| OrdinarySharesNumber | 126.75M | 126.06M | 125.39M |
| ShareIssued | 126.75M | 126.06M | 125.39M |
| NetDebt | 10.24M | ||
| TotalDebt | 15.17M | 14.55M | 10.70M |
| TangibleBookValue | 13.41M | 62.18M | 128.62M |
| InvestedCapital | 28.58M | 76.73M | 139.32M |
| WorkingCapital | 15.62M | 62.95M | 126.81M |
| NetTangibleAssets | 13.41M | 62.18M | 128.62M |
| CommonStockEquity | 13.41M | 62.18M | 128.62M |
| TotalCapitalization | 26.67M | 75.22M | 138.94M |
| TotalEquityGrossMinorityInterest | 13.41M | 62.18M | 128.62M |
| StockholdersEquity | 13.41M | 62.18M | 128.62M |
| GainsLossesNotAffectingRetainedEarnings | 8.00K | -197.00K | 0.00 |
| OtherEquityAdjustments | 8.00K | -197.00K | |
| TreasuryStock | 0.00 | ||
| RetainedEarnings | -361.64M | -304.70M | -229.48M |
| AdditionalPaidInCapital | 374.76M | 366.80M | 357.82M |
| CapitalStock | 278.00K | 278.00K | 278.00K |
| CommonStock | 278.00K | 278.00K | 278.00K |
| PreferredStock | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 30.90M | 44.22M | 38.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 13.30M | 13.28M | 10.56M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | ||
| DerivativeProductLiabilities | 0.00 | ||
| NonCurrentAccruedExpenses | 0.00 | 1.00K | |
| NonCurrentDeferredLiabilities | 35.00K | 236.00K | 236.00K |
| NonCurrentDeferredTaxesLiabilities | 35.00K | 236.00K | 236.00K |
| LongTermDebtAndCapitalLeaseObligation | 13.26M | 13.04M | 10.32M |
| LongTermDebt | 13.26M | 13.04M | 10.32M |
| LongTermProvisions | 236.00K | ||
| CurrentLiabilities | 17.61M | 30.94M | 27.49M |
| CurrentDebtAndCapitalLeaseObligation | 1.91M | 1.50M | 376.00K |
| CurrentDebt | 1.91M | 1.50M | 376.00K |
| OtherCurrentBorrowings | 406.00K | 391.00K | 376.00K |
| CurrentNotesPayable | 1.50M | 1.11M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.56M | 2.57M | 2.29M |
| PayablesAndAccruedExpenses | 14.14M | 26.87M | 24.82M |
| CurrentAccruedExpenses | 1.78M | 8.80M | 2.23M |
| InterestPayable | 21.00K | 176.00K | 32.00K |
| Payables | 12.36M | 18.07M | 22.60M |
| DuetoRelatedPartiesCurrent | 10.57M | 12.77M | 19.41M |
| AccountsPayable | 1.78M | 5.29M | 3.19M |
| TotalAssets | 44.31M | 106.40M | 166.67M |
| TotalNonCurrentAssets | 11.08M | 12.51M | 12.37M |
| OtherNonCurrentAssets | 172.00K | ||
| NonCurrentDeferredAssets | 0.00 | ||
| NetPPE | 11.08M | 12.51M | 12.37M |
| AccumulatedDepreciation | -5.87M | -3.62M | -1.98M |
| GrossPPE | 16.95M | 16.14M | 14.35M |
| Leases | 576.00K | 403.00K | 0.00 |
| ConstructionInProgress | 128.00K | 65.00K | 199.00K |
| OtherProperties | 3.15M | 1.83M | |
| MachineryFurnitureEquipment | 16.24M | 15.67M | 14.15M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 33.23M | 93.89M | 154.30M |
| OtherCurrentAssets | 840.00K | 522.00K | 343.00K |
| RestrictedCash | 105.00K | 1.09M | 172.00K |
| PrepaidAssets | 1.48M | 5.03M | 8.51M |
| Receivables | 414.00K | 414.00K | 393.00K |
| DuefromRelatedPartiesCurrent | 414.00K | 414.00K | 393.00K |
| AccountsReceivable | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 30.39M | 86.83M | 144.88M |
| OtherShortTermInvestments | 25.46M | 53.35M | 0.00 |
| CashAndCashEquivalents | 4.93M | 33.48M | 144.88M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -58.04M | -57.79M | -82.31M |
| RepaymentOfDebt | -1.59M | -430.00K | -2.77M |
| IssuanceOfDebt | 0.00 | 2.00M | |
| IssuanceOfCapitalStock | 0.00 | 193.87M | |
| CapitalExpenditure | -803.00K | -1.87M | -1.32M |
| InterestPaidSupplementalData | 799.00K | 367.00K | 581.00K |
| EndCashPosition | 5.04M | 34.57M | 145.06M |
| BeginningCashPosition | 34.57M | 145.06M | 31.20M |
| ChangesInCash | -29.53M | -110.49M | 113.86M |
| FinancingCashFlow | -1.14M | -167.00K | 196.17M |
| CashFlowFromContinuingFinancingActivities | -1.14M | -167.00K | 196.17M |
| NetOtherFinancingCharges | 2.90M | ||
| ProceedsFromStockOptionExercised | 454.00K | 263.00K | 170.00K |
| NetPreferredStockIssuance | 0.00 | 122.79M | |
| PreferredStockIssuance | 0.00 | 122.79M | |
| NetCommonStockIssuance | 0.00 | 71.08M | |
| CommonStockIssuance | 0.00 | 71.08M | |
| NetIssuancePaymentsOfDebt | -1.59M | -430.00K | -771.00K |
| NetLongTermDebtIssuance | -1.59M | -430.00K | -771.00K |
| LongTermDebtPayments | -1.59M | -430.00K | -2.77M |
| LongTermDebtIssuance | 0.00 | 2.00M | |
| InvestingCashFlow | 28.84M | -54.39M | -1.32M |
| CashFlowFromContinuingInvestingActivities | 28.84M | -54.39M | -1.32M |
| NetInvestmentPurchaseAndSale | 29.65M | -52.53M | 0.00 |
| SaleOfInvestment | 93.59M | 55.00M | 0.00 |
| PurchaseOfInvestment | -63.94M | -107.53M | 0.00 |
| NetPPEPurchaseAndSale | -803.00K | -1.87M | -1.32M |
| PurchaseOfPPE | -803.00K | -1.87M | -1.32M |
| OperatingCashFlow | -57.24M | -55.93M | -80.99M |
| CashFlowFromContinuingOperatingActivities | -57.24M | -55.93M | -80.99M |
| ChangeInWorkingCapital | -8.54M | 9.82M | 12.88M |
| ChangeInOtherWorkingCapital | 2.25M | ||
| ChangeInOtherCurrentLiabilities | -201.00K | -1.00K | -12.00K |
| ChangeInPayablesAndAccruedExpense | -11.58M | 6.54M | 15.35M |
| ChangeInAccruedExpense | -8.03M | 6.85M | 1.77M |
| ChangeInPayable | -3.55M | -307.00K | 13.58M |
| ChangeInAccountPayable | -3.51M | 2.10M | 2.17M |
| ChangeInPrepaidAssets | 3.24M | 3.30M | -4.70M |
| ChangeInReceivables | -1.00K | -21.00K | -5.00K |
| ChangesInAccountReceivables | 0.00 | 26.00K | |
| OtherNonCashItems | 51.00K | 53.00K | 3.21M |
| StockBasedCompensation | 7.51M | 8.71M | 30.41M |
| AmortizationOfSecurities | -1.55M | -1.02M | 0.00 |
| DepreciationAmortizationDepletion | 2.23M | 1.68M | 1.10M |
| DepreciationAndAmortization | 2.23M | 1.68M | 1.10M |
| Depreciation | 2.23M | 1.68M | 1.10M |
| OperatingGainsLosses | 43.00K | 8.58M | |
| GainLossOnInvestmentSecurities | 8.58M | ||
| NetIncomeFromContinuingOperations | -56.93M | -75.22M | -137.18M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for VAXX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|